Danaher Corp /DE/ (DHR) is a globally recognized leader in the science and technology sector, providing professional, medical, industrial, and commercial solutions. Established in 1969 and headquartered in Washington, D.C., it has grown into a multinational corporation with remarkable influence and reach. The company is listed on the New York Stock Exchange under the symbol DHR.
Danaher operates in three principal business segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Its comprehensive portfolio includes various products and services that are used in modern scientific research, medical diagnostics, and environmental monitoring. Some of the leading brands under the Danaher umbrella include Leica Microsystems, Beckman Coulter, and AB SCIEX.
The Life Sciences segment focuses on research and development to deliver innovative solutions in the areas of molecular biology and genomics. Meanwhile, the Diagnostic segment is dedicated to improving patient outcomes by offering precise diagnostic information that guides critical decisions in healthcare. On the other hand, the Environmental & Applied Solutions segment provides essential solutions for water quality analysis, product identification, and services that guarantee safety and protect global resources.
Danaher is recognized for its unique corporate culture, known as the "Danaher Business System” (DBS), which is driven by continuous improvement and customer satisfaction. This strategy involves relentless focus on process and its continuous improvement. DBS has powered Danaher's transformation from a discrete manufacturing company into a science and technology leader.
As of 2022, Danaher employs about 60,000 associates, spread across 20+ countries. Its revenue figures have been consistently impressive, reflecting its continuing success in a fiercely competitive sector. The company has also earned a reputation as a stand-out performer in delivering shareholder value, underpinned by innovation, thorough operational execution, and strategic investment in sustainable growth initiatives.
Corporate responsibility and sustainability are two essential pillars of Danaher's model. The company is committed to the responsible management of environmental, social, and governance (ESG) issues which is vital for sustainable long-term performance.
Its success shows that, at Danaher, innovation and responsibility go hand in hand. Each new product and service introduction is a testament to its enduring mission to "Help Realize Life's Potential” - a goal reflected genuinely in the range of scientific, healthcare, and environmental breakthroughs that the company has been part of in the last half-century.
In summary, Danaher Corp is remarkable for more than just its size and reach. Its long-standing commitment to innovation, strategic execution, and responsible corporate stewardship continue to drive the company's overall success.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
DODGE & COX has significantly increased its stake in Danaher (DHR), adding over 9.8 million shares to its portfolio as of the Q3 2026 report period. This move, representing a 3821.0% increase, is part of broader institutional investor activity for DHR, which also includes substantial decreases by other major funds. The article also details recent insider trading, government contracts, congressional stock trades, and analyst ratings for Danaher.
Bio-Techne (TECH) recently reported first-quarter results with sales of US$299.71 million and net income of US$28.29 million, along with a US$0.08 quarterly dividend related to its Merck KGaA transaction. The stock has seen significant year-to-date and annual returns, but Simply Wall St's analyst consensus suggests it is modestly overvalued with a fair value estimate of $70.73 compared to its recent close of $72.84. Investors are weighing the softer quarterly earnings against steady sales and the potential benefits of the Merck deal and recurring revenue from consumables.
RenaissanceRe Holdings Ltd. (NYSE:RNR) announced a quarterly dividend of $0.41 per share, equating to an annualized $1.64 and a 0.5% yield. The dividend, payable December 31 to shareholders of record December 15, appears well covered by earnings with a current payout ratio of 4.5% and an expected 3.9% next year. The company recently reported quarterly EPS of $12.71, surpassing consensus estimates, despite revenue of $1.69 billion falling short of expectations.
Matthew McGrew, Executive Vice President at Danaher (NYSE: DHR), recently exercised stock options for 17,385 shares valued at $2,563,070, as detailed in an SEC filing on November 10. This transaction highlights insider activity and follows Danaher's strategic shift to life sciences and diagnostics. The article also provides a financial overview of Danaher, noting its positive revenue growth, strong gross margin, and favorable debt management, alongside an analysis of its valuation metrics.
The global in vitro toxicology testing market, valued at US$14 billion in 2025, is projected to reach US$27.4 billion by 2032, driven by regulatory shifts away from animal testing and advancements in human-relevant models, AI, and high-throughput screening. This growth is significantly influenced by pharmaceutical, biotechnology, cosmetics, and food safety industries adopting these technologies to accelerate safety assessments and reduce development costs. Key players like Thermo Fisher Scientific, Merck, Eurofins, and Bio-Rad are at the forefront of this market disruption.
Biodesix, Inc. will present new data from its tumor-informed and tumor-naïve molecular monitoring programs at the Association for Molecular Pathology (AMP) 2026 Annual Meeting. The company will showcase proprietary bioinformatics, ultrasensitive molecular detection, and collaborations with Bio-Rad Laboratories and Thermo Fisher Scientific to advance scalable molecular residual disease (MRD) solutions. These solutions aim to improve patient access to advanced MRD testing by leveraging partner platforms already installed in laboratories worldwide.
This guide provides an overview of Clarivate's Cortellis suite, a life sciences intelligence platform integrating biomedical, clinical, regulatory, and commercial data. It details the platform's utility for research sponsors, biotechnology firms, and CROs in assessing pipelines, designing clinical protocols, and navigating global compliance. The article also covers its modular intelligence domains, access methods, strengths, limits, and alternatives.